Polaprezinc (Zinc–l-Carnosine Complex) as an Add-on Therapy for Binge Eating Disorder and Bulimia Nervosa, and the Possible Involvement of Zinc Deficiency in These Conditions

Abstract

Background Zinc plays an important role in appetite regulation. l -Carnosine, an endogenous dipeptide, may also regulate eating behavior via its histaminergic and antiglutamatergic properties. Polaprezinc (zinc– l -carnosine complex) is a medication for gastric ulcers. A small case series reported successful treatment of binge eating with add-on polaprezinc. Methods This was an open trial of add-on polaprezinc in patients with binge eating disorder (BED; n = 22) or bulimia nervosa (BN; n = 7) receiving antidepressants. A 4-week baseline period was followed by a 16-week polaprezinc treatment at 150 mg/d (containing 34 mg zinc and 116 mg l -carnosine) in addition to ongoing psychotropic medications. We also assessed their zinc status via a laboratory index and zinc deficiency–related symptoms. Results At the study end, both conditions showed a significant reduction in the 4-week frequency of combined objective and subjective binge eating episodes, the 4-week frequency of days when at least 1 such episode occurred (only in BED), several aspects of eating disorder psychopathology (rated by the Eating Disorder Examination–Questionnaire), and comorbid depressive symptoms (rated by the 16-item Quick Inventory of Depressive Symptomatology [Self-Report]). Serum copper/zinc ratio decreased from 1.4 to 1.1 on average in both conditions. All patients had multiple zinc deficiency–related symptoms at baseline that substantially improved after polaprezinc treatment. Overall, the effectiveness of polaprezinc was greater in BED patients than in BN patients, with minor adverse effects. Conclusions These findings offer preliminary evidence for the effectiveness of polaprezinc in treating BED and BN and suggest the involvement of zinc deficiency in these conditions.

Significance of Zinc Replacement Therapy After Pancreaticoduodenectomy

“…Zinc deficiency is exhibited in a variety of clinical manifestations. It has been reported that it causes various symptoms, such as dermatitis, diarrhoea, immunocompromised hostism, hypogonadism in men, delayed wound healing and dysgeusia (14)(15)(16)(17)(18)(19).…”

Pharmakotherapie bei Essstörungen

“…Die "Zinkmangelhypothese" wurde auch auf die BN und BES angewendet. Eine rezente Pilotstudie berichtet von reduzierten Essanfällen und weiteren positiven Effekten durch Polaprezink (Kombination aus Zink und l-Carnosin) als Zusatztherapie [23]. Trotz möglicher theoretischer Wirkmechanismen kann der Einsatz von Ketamin aufgrund bisher empirisch nicht gesicherter Wirksamkeit und dem Sicherheitsprofil bei Patient*innen mit AN nicht empfohlen werden.…”

Anorexia Nervosa—What Has Changed in the State of Knowledge about Nutritional Rehabilitation for Patients over the Past 10 Years? A Review of Literature

“…In addition, Zn has been shown to affect glutaminergic and serotonergic regulation as well as neuroproliferation and systemic anti-inflammatory effects [64][65][66][67]. In a study of patients with eating disorders, Zn levels were found to be reduced [68]. Rosenblum also described a case of Zn deficiency-induced cardiomyopathy in a patient diagnosed with acute phase AN in whom other possible etiopathogenetic factors were excluded.…”